GHK-PGP and proline-containing GHK analogs exert anxiolytic effects in punished behavior test
Background
Anxiety disorders represent a significant global health burden, often managed with pharmaceuticals that carry considerable side effects, including sedation, dependence, and withdrawal symptoms. This necessitates the exploration of novel therapeutic agents with improved safety profiles. Regulatory peptides, such as the synthetic heptapeptide Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) and hexapeptide Semax, have emerged as promising candidates, demonstrating both anxiolytic and psychostimulant properties. Notably, both Selank and Semax incorporate the tripeptide Pro-Gly-Pro (PGP) as a C-terminal fragment, suggesting a potential independent role for PGP in their observed effects. The tripeptide Gly-His-Lys (GHK) is also a well-known endogenous peptide with various biological activities, but its role in anxiety has been less explored. This study investigates whether combining GHK with PGP, or other proline-containing sequences, could yield novel anxiolytic compounds.
Study Design
Researchers investigated the anxiolytic activity of several peptides in male rats using the Vogel conflict test, a standard model for assessing punished behavior. The study compared the effects of Gly-His-Lys-Pro-Gly-Pro (GHK-PGP) against its constituent peptides, Gly-His-Lys (GHK) and Pro-Gly-Pro (PGP), as well as two other proline-containing GHK analogs: Gly-His-Lys-Gly-Pro (GHK-GP) and Gly-His-Lys-Pro (GHK-P). Peptides were administered via intraperitoneal injection, and anxiolytic activity was assessed by measuring changes in punished behavior, specifically the number of punished responses, following administration of various doses. The study aimed to identify which peptide sequences, particularly those incorporating proline, contributed to anxiolytic effects.
Results
The study revealed distinct anxiolytic profiles among the tested peptides. GHK peptide, when administered alone, demonstrated no anxiolytic effect in the Vogel conflict test. In contrast, PGP peptide, a known component of other anxiolytic drugs, produced a significant anxiolytic effect at certain doses. Crucially, the novel peptide GHK-PGP also exhibited anxiolytic activity, mirroring the effect seen with PGP alone. This suggests that the anxiolytic effect of GHK-PGP is primarily driven by the PGP component, potentially in the absence of any blocking effect from the GHK sequence. Further supporting the role of proline-containing sequences, the peptides GHK-P and GHK-GP also demonstrated anxiolytic effects. This finding indicates that various proline-containing amino acid sequences attached to GHK can confer anxiolytic activity. The researchers hypothesize that the presence of proline in these sequences is a key determinant for their observed anxiolytic properties.
The anxiolytic effect of GHK-PGP is presumably determined by the action of PGP in the absence of the blocking effect of GHK.
Key Findings
- GHK-PGP peptide demonstrated anxiolytic effects in the
Vogel conflict testin male rats. - PGP peptide alone also produced anxiolytic effects at specific doses.
- GHK peptide itself showed no anxiolytic effect.
- Other proline-containing GHK analogs, GHK-P and GHK-GP, also exhibited anxiolytic activity.
- The anxiolytic effect of GHK-PGP is likely attributed to the PGP component, uninhibited by GHK.
Why It Matters
This research highlights the potential of novel peptide combinations, particularly those involving proline-rich sequences, as future anxiolytic therapies. The finding that GHK-PGP and other proline-containing GHK analogs exert anxiolytic effects suggests a new avenue for drug development, potentially leading to compounds with fewer side effects than conventional anxiolytics. For peptide users and biohackers, this study offers insights into the specific structural elements (like PGP and other proline-containing sequences) that contribute to anxiolytic activity, which could inform the design or selection of peptides for mood and stress management. While preclinical, this work lays the groundwork for further investigation into the therapeutic potential of these peptides, moving closer to understanding how specific peptide sequences can be leveraged to modulate neurological functions. The practical takeaway is that proline-containing peptide fragments linked to GHK show promise for anxiety reduction, warranting further exploration into their mechanisms and optimal dosing.
ghk-pgp
pgp
ghk
anxiolytic
anxiety
preclinical-animal